Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.

[1]  C. Hofmeister,et al.  Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  R. Advani,et al.  Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma , 2016 .

[3]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[4]  A. Florek,et al.  Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma , 2016, American journal of therapeutics.

[5]  Elizabeth Wager,et al.  Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3 , 2015, Annals of Internal Medicine.

[6]  M. Tetzlaff,et al.  Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Byeong-Bae Park,et al.  Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial , 2015, Annals of Hematology.

[8]  R. Advani,et al.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Savage,et al.  Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Sonali M. Smith,et al.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Wilson,et al.  CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature , 2015, Leukemia & lymphoma.

[12]  T. Ruzicka,et al.  Treatment of cutaneous T‐cell lymphoma with oral alitretinoin , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  J. Jorgensen,et al.  Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. , 2015, Blood.

[14]  T. Reiman,et al.  Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma , 2015, Cancer.

[15]  R. Advani,et al.  A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma , 2015, British journal of haematology.

[16]  Kazuhito Yamamoto.  [Anti-CCR4 monoclonal antibody]. , 2015, Nihon rinsho. Japanese journal of clinical medicine.

[17]  C. Volteau,et al.  Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients. , 2015, Acta dermato-venereologica.

[18]  W. Kim,et al.  A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) , 2014 .

[19]  T. Kuzel,et al.  A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) , 2014 .

[20]  S. Whittaker,et al.  Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study , 2014 .

[21]  I. Flinn,et al.  Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma , 2014 .

[22]  B. Coiffier,et al.  A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL) , 2014 .

[23]  R. Advani,et al.  Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma , 2014 .

[24]  John D. Roberts,et al.  Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results , 2014 .

[25]  K. Savage,et al.  Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat , 2014 .

[26]  P. Frankel,et al.  Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies , 2014 .

[27]  J. Byrd,et al.  The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) , 2014 .

[28]  E. Baloglu,et al.  Nucleo-cytoplasmic transport as a therapeutic target of cancer , 2014, Journal of Hematology & Oncology.

[29]  M. Goswami,et al.  Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome , 2014, Clinical Cancer Research.

[30]  M. Talbott,et al.  Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma , 2014, OncoTargets and therapy.

[31]  B. Coiffier,et al.  Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma , 2014, Biomarker Research.

[32]  R. Dummer,et al.  Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Sonali M. Smith,et al.  Phosphoinositide 3-kinase inhibitors in lymphoma , 2014, Current opinion in oncology.

[34]  R. Poole.  Belinostat: First Global Approval , 2014, Drugs.

[35]  M. Duvic,et al.  Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. , 2014, Clinical lymphoma, myeloma & leukemia.

[36]  M. Ogura,et al.  Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma , 2014, Cancer science.

[37]  P. Zinzani,et al.  Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine , 2014, Annals of Hematology.

[38]  S. Horwitz,et al.  Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator’s choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL). , 2014 .

[39]  L. Hughey,et al.  Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL). , 2014 .

[40]  R. Advani,et al.  Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. , 2014, Blood.

[41]  M. Taniwaki,et al.  Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Scott E. Smith,et al.  Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies , 2014, Journal of Hematology & Oncology.

[43]  R. Dummer,et al.  Novel therapies for cutaneous T-cell lymphoma: what does the future hold? , 2014, Expert opinion on investigational drugs.

[44]  S. Dusza,et al.  Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. , 2014, Blood.

[45]  C. Papadimitriou,et al.  Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. , 2014, Critical reviews in oncology/hematology.

[46]  B. Coiffier,et al.  Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses , 2014, Journal of Hematology & Oncology.

[47]  R. Greil,et al.  Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial , 2014, Annals of Hematology.

[48]  D. Weisenburger,et al.  Differences in incidence and trends of haematological malignancies in Japan and the United States , 2013, British journal of haematology.

[49]  I. Lossos,et al.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  B. Coiffier,et al.  The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. , 2014, Seminars in hematology.

[51]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[52]  G. Alves,et al.  Pathology and Genetics , 1998 .

[53]  L. Trümper,et al.  [Treatment of peripheral T-cell lymphoma]. , 2014, Deutsche medizinische Wochenschrift.

[54]  S. Horwitz,et al.  Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  N. Schmitz,et al.  Allogeneic transplantation in T-cell lymphomas. , 2014, Seminars in hematology.

[56]  P. Corradini,et al.  Autologous stem cell transplantation for T-cell lymphomas. , 2014, Seminars in hematology.

[57]  A. Evens,et al.  Chemotherapeutic advancements in peripheral T-cell lymphoma. , 2014, Seminars in hematology.

[58]  J. Fromm,et al.  Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin , 2013, OncoTargets and therapy.

[59]  Bonnie Tillotson,et al.  PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. , 2013, Chemistry & biology.

[60]  L. Guerra,et al.  High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients , 2013 .

[61]  K. Horibe,et al.  Safety and Clinical Activity Of Crizotinib In Patients With ALK-Rearranged Hematologic Malignancies , 2013 .

[62]  M. Weichenthal,et al.  Response Of Rare Variants Of Cutaneous T Cell Lymphoma (CTCL) To Treatment With Bexarotene. A Prospective German DeCOG Trial , 2013 .

[63]  R. Advani,et al.  Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma , 2013 .

[64]  D. Neville,et al.  An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL , 2013 .

[65]  D. Budman,et al.  Profile of panobinostat and its potential for treatment in solid tumors: an update , 2013, OncoTargets and therapy.

[66]  M. Weinstock,et al.  Changing incidence trends of cutaneous T-cell lymphoma. , 2013, JAMA dermatology.

[67]  R. Cowan,et al.  Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma , 2013, British Journal of Cancer.

[68]  Sonali M. Smith,et al.  A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T‐cell lymphomas , 2013, British journal of haematology.

[69]  B. Coiffier,et al.  A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. , 2013, European journal of cancer.

[70]  H. Prince,et al.  Panobinostat in lymphoid and myeloid malignancies , 2013, Expert opinion on investigational drugs.

[71]  H. Prince,et al.  Romidepsin for peripheral T-cell lymphoma , 2013, Expert review of hematology.

[72]  P. Corradini,et al.  Current state of art for transplantation paradigms in peripheral T-cell lymphomas , 2013, Expert review of hematology.

[73]  H. Prince,et al.  Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. , 2013, Clinical lymphoma, myeloma & leukemia.

[74]  P. Zinzani,et al.  belinostat In Relapsed Or Refractory Peripheral T-cell Lymphoma (r/r Ptcl) Subtype Angioimmunoblastic T-cell Lymphoma (aitl): Results From The Pivotal Belief Trial : 153 , 2013 .

[75]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[76]  R. Gascoyne,et al.  Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  S. Horwitz,et al.  Treatment of Peripheral T-cell Lymphoma: Are We Data Driven or Driving the Data? , 2013, Current Treatment Options in Oncology.

[78]  N. Schmitz,et al.  ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  J. Briones,et al.  Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma , 2013, Haematologica.

[80]  D. Fivenson,et al.  Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma , 2013, Leukemia & lymphoma.

[81]  C. Dasanu,et al.  Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma , 2013, Expert opinion on pharmacotherapy.

[82]  S. Parker,et al.  Acitretin for the treatment of cutaneous T-cell lymphoma. , 2013, Journal of the American Academy of Dermatology.

[83]  M. Sokołowska-Wojdyło,et al.  Oral retinoids and rexinoids in cutaneous T-cell lymphomas , 2013, Postepy dermatologii i alergologii.

[84]  C. Flowers,et al.  Incidence and survival patterns of cutaneous T-cell lymphomas in the United States , 2013, Leukemia & lymphoma.

[85]  R. Advani,et al.  A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study , 2013, Leukemia & lymphoma.

[86]  R. Cowan,et al.  U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T‐cell lymphoma , 2013, The British journal of dermatology.

[87]  D. Fivenson,et al.  Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome , 2012, Leukemia & lymphoma.

[88]  L. Specht,et al.  Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  R. Houot,et al.  Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  J. Becker,et al.  Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. , 2013, European journal of cancer.

[91]  Y. Ko,et al.  Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma , 2013, Investigational New Drugs.

[92]  P. Liu,et al.  Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma , 2013, Medical Oncology.

[93]  M. Weichenthal,et al.  Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  Y. Chan,et al.  Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response , 2012 .

[95]  Carmine F. Palermo,et al.  Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate. , 2012 .

[96]  U. Jäger,et al.  Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation. , 2012 .

[97]  Y. Kwong,et al.  SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. , 2012, Blood.

[98]  H. Wada,et al.  Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T‐cell lymphoma , 2012, The Journal of dermatology.

[99]  K. Matsuo,et al.  Increase in incidence of adult T‐cell leukemia/lymphoma in non‐endemic areas of Japan and the United States , 2012, Cancer science.

[100]  L. Wilson,et al.  Age, race, sex, stage, and incidence of cutaneous lymphoma. , 2012, Clinical lymphoma, myeloma & leukemia.

[101]  A. Neugut,et al.  Increasing incidence of enteropathy‐associated T‐cell lymphoma in the United States, 1973‐2008 , 2012, Cancer.

[102]  M. Ogura,et al.  Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer‐cell malignancies , 2012, Cancer science.

[103]  R. Advani,et al.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  K. McKeage,et al.  Mogamulizumab: first global approval. , 2012, Drugs.

[105]  M. Duvic,et al.  Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas. , 2012, Clinical lymphoma, myeloma & leukemia.

[106]  D. Fisher,et al.  Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. , 2012, Blood.

[107]  P. Zinzani,et al.  Overview of alemtuzumab therapy for the treatment of T-cell lymphomas , 2012, Leukemia & lymphoma.

[108]  A. Ranki,et al.  Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. , 2012, Acta dermato-venereologica.

[109]  S. Horwitz,et al.  Management of cutaneous T cell lymphoma: new and emerging targets and treatment options , 2012, Cancer management and research.

[110]  R. Ueda,et al.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  Matthew Greenwood,et al.  Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  R. Suzuki,et al.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  Rachel E. Gershman,et al.  Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays , 2011, Clinical Cancer Research.

[114]  R. Dummer,et al.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. , 2011, Blood.

[115]  S. Pileri,et al.  Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified , 2011, Leukemia & lymphoma.

[116]  A. Rademaker,et al.  Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins , 2011, Clinical Cancer Research.

[117]  J. Vose,et al.  Peripheral T-cell lymphoma. , 2011, Blood.

[118]  S. Steinberg,et al.  Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. , 2011, Blood.

[119]  K. Savage,et al.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  C. Messa,et al.  Crizotinib in anaplastic large-cell lymphoma. , 2011, The New England journal of medicine.

[121]  P. Gaulard,et al.  Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. , 2011, Blood.

[122]  O. Akilov,et al.  Therapeutic advances in cutaneous T-cell lymphoma. , 2011, Skin therapy letter.

[123]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[124]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  T. Reiman,et al.  Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma , 2010, Cancer.

[126]  M. Dogan,et al.  Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP , 2010, Medical oncology.

[127]  F. Ravandi,et al.  Forodesine: review of preclinical and clinical data. , 2010, Future oncology.

[128]  R. Pazdur,et al.  Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary , 2010, Clinical Cancer Research.

[129]  W. Sterry,et al.  Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  S. Pileri,et al.  Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[131]  K. Ohshima,et al.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  M. Dreyling,et al.  A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas , 2010, Leukemia & lymphoma.

[133]  A. Rademaker,et al.  Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center , 2009, Leukemia & lymphoma.

[134]  E. Olsen,et al.  Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. , 2009, Clinical lymphoma & myeloma.

[135]  S. Steinberg,et al.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  H. Kantarjian,et al.  Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  V. Seshan,et al.  Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  P. Morel,et al.  Gemcitabine treatment in cutaneous T‐cell lymphoma: a multicentre study of 23 cases , 2009, The British journal of dermatology.

[139]  J. Scarisbrick,et al.  Bexarotene therapy for mycosis fungoides and Sézary syndrome , 2009, The British journal of dermatology.

[140]  S. Devesa,et al.  Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. , 2009, Blood.

[141]  Y. Kim,et al.  Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  Y. Ko,et al.  Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. , 2008, Annals of Oncology.

[143]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  Gordon K Smyth,et al.  Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma , 2008, Clinical Cancer Research.

[145]  B. Dréno,et al.  Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. , 2008, Archives of dermatology.

[146]  T. Okamura,et al.  Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemia , 2008, Cancer science.

[147]  D. Neville,et al.  Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390–bisFv(UCHT1) , 2008, Cancer Immunology, Immunotherapy.

[148]  K. Karube,et al.  Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T‐cell and NK‐cell lymphomas: Analysis of 490 cases , 2008, Pathology international.

[149]  Jordi Martínez,et al.  GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study , 2007, European journal of haematology.

[150]  V. Gandhi,et al.  Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. , 2007, Seminars in oncology.

[151]  S. Pileri,et al.  Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  T. Robak,et al.  Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application. , 2007, Mini reviews in medicinal chemistry.

[153]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  M. Weinstock,et al.  Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. , 2007, Archives of dermatology.

[155]  P. Quaglino,et al.  Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. , 2007, Haematologica.

[156]  T. Kuzel,et al.  Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma , 2007, Cancer.

[157]  N. Pimpinelli,et al.  Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. , 2007, Haematologica.

[158]  Dan Jones,et al.  Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma , 2007, British journal of haematology.

[159]  A. Horwich,et al.  Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. , 2007, Haematologica.

[160]  R. Advani,et al.  Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine , 2007, Leukemia & lymphoma.

[161]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[162]  E. Olsen,et al.  Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study. , 2006 .

[163]  Masahiro Takigawa,et al.  Chemokine Receptor Expression in Cutaneous T cell and NK/T-cell Lymphomas: Immunohistochemical Staining and In Vitro Chemotactic Assay , 2006, The American journal of surgical pathology.

[164]  R. Kurzrock,et al.  Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. , 2006, Clinical lymphoma & myeloma.

[165]  K. Karube,et al.  Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders , 2006, British Journal of Dermatology.

[166]  R. Dummer,et al.  EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. , 2006, European journal of cancer.

[167]  A. Glasmacher,et al.  Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma , 2006, Cancer investigation.

[168]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[169]  F. Foss,et al.  A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. , 2005, Blood.

[170]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[171]  A. Horwich,et al.  Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma , 2005, British Journal of Cancer.

[172]  S. Pileri,et al.  Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. , 2005, Haematologica.

[173]  M. Baccarani,et al.  Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. , 2005, Haematologica.

[174]  M. Territo,et al.  Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. , 2004, Clinical lymphoma.

[175]  M. Erlanson,et al.  A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. , 2004, Blood.

[176]  A. Tsimberidou,et al.  Phase II study of pentostatin in advanced T‐cell lymphoid malignancies , 2004, Cancer.

[177]  D. Peterson,et al.  Novel therapies. , 2004, Seminars in oncology nursing.

[178]  M. Kashani-Sabet,et al.  Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. , 2003, Journal of the American Academy of Dermatology.

[179]  H. Prince,et al.  Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab , 2003, European journal of haematology.

[180]  A. Hauschild,et al.  Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma , 2003, Cancer.

[181]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[182]  A. Varghese,et al.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.

[183]  G. Juliusson,et al.  Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. , 2003, Blood.

[184]  A. Zelenetz,et al.  Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[185]  A. Zelenetz,et al.  Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression , 2003, Leukemia & lymphoma.

[186]  T. Kuzel,et al.  Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). , 2002, Clinical lymphoma.

[187]  P. Vodvářka,et al.  Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. , 2001, European journal of haematology. Supplementum.

[188]  M. Duvic,et al.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[189]  G. Wood,et al.  Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.

[190]  N. Nguyen,et al.  Treatment of refractory T‐cell malignancies using gemcitabine , 2001, British journal of haematology.

[191]  A. Oseroff,et al.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[192]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[193]  S. Pileri,et al.  Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  C. Meijer,et al.  Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment , 2000 .

[195]  D. Catovsky,et al.  Eovist Injection and Resovist Injection: two new liver-specific contrast agents for MRI. , 2000 .

[196]  F. Foss.  Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies. , 2000, Seminars in oncology.

[197]  H. Döhner,et al.  Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer. , 2000, Seminars in oncology.

[198]  R. Willemze,et al.  Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. , 2000, Archives of dermatology.

[199]  U. Wollina,et al.  Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. , 2000, Journal of the American Academy of Dermatology.

[200]  R. Kurzrock,et al.  Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[201]  丹司 望,et al.  Gemcitabine + cisplatin , 2009 .

[202]  S. Pileri,et al.  Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[203]  M. Ratain,et al.  Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. , 1998, Journal of the American Academy of Dermatology.

[204]  M. Ratain,et al.  Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. , 1998, Blood.

[205]  J. Degraw,et al.  A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice , 1998, Cancer Chemotherapy and Pharmacology.

[206]  G. Petroni,et al.  Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. , 1997, Journal of the American Academy of Dermatology.

[207]  M. Kashani-Sabet,et al.  Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. , 1996, Journal of the American Academy of Dermatology.

[208]  F. Cavalli,et al.  Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. , 1996, Oncology.

[209]  E. Olsen.  Interferon in the treatment of cutaneous T‐cell lymphoma , 2003, Hematology/oncology clinics of North America.

[210]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[211]  K. Maclennan,et al.  The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[212]  S. Tucker,et al.  ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[213]  W. Wilson,et al.  EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  S. Weitzman,et al.  Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[215]  R. Peters.  Nucleo-cytoplasmic transport , 1988 .

[216]  S. Jagannath,et al.  Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). , 1988, Blood.

[217]  D. Sainty,et al.  [Peripheral T cell lymphoma]. , 1984, Nouvelle revue francaise d'hematologie.

[218]  S. Lewis,et al.  British Committee for Standards in Haematology , 1969 .